Artículo
Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease
Fecha de publicación:
04/2018
Editorial:
Wiley Blackwell Publishing, Inc
Revista:
Hemodialysis International
ISSN:
1492-7535
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Hepatitis C virus infection (HCV) is highly prevalent in patients with chronic kidney disease (CKD) and kidney transplant recipients. Little information exists on treatment in patients with CKD stages 2 to 3, where CKD progression might be slowed by HCV treatment. These patients are not considered a high priority for HCV treatment in most international guidelines. Although some recently published guidelines propose universal treatment, others are still recommending it only in high priority groups. In this review, we evaluate current evidence of HCV infection impact on CKD progression, on cardiovascular and metabolic risk, and the benefits of HCV infection treatment to improve cardiovascular and metabolic outcomes. We made special focus on the benefits of HCV infection treatment in patients with stages 2 to 3 CKD to avoid CKD progression.
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(CEMIC-CONICET)
Articulos de CENTRO DE EDUCACION MEDICA E INVESTIGACIONES CLINICAS "NORBERTO QUIRNO"
Articulos de CENTRO DE EDUCACION MEDICA E INVESTIGACIONES CLINICAS "NORBERTO QUIRNO"
Citación
Ridruejo, Ezequiel; Mendizabal, Manuel; Silva, Marcelo O.; Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease; Wiley Blackwell Publishing, Inc; Hemodialysis International; 22; 4-2018; S97-S103
Compartir
Altmétricas